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Background and Objectives. Resistant and susceptible mouse strains to experimental autoimmune encephalomyelitis (EAE), an
inducible demyelinating experimental disease serving as animal model for multiple sclerosis, have been described. We aimed to
explore MHC-independent mechanisms inducing resistance to EAE. Methods. For EAE induction, female C57BL/6 (susceptible
strain) and CD1 (resistant outbred strain showing heterogeneous MHC antigens) mice were immunized with the 35–55 peptide
of myelin oligodendrocyte glycoprotein (MOG
35−55
). We studied T cell proliferation, regulatory and effector cell subpopulations,
intracellular and serum cytokine patterns, and titers of anti-MOG serum antibodies. Results. Upon immunization with MOG
35−55
,
T lymphocytes from susceptible mice but not that of resistant strain were capable of proliferating when stimulated with MOG
35−55
.
Accordingly, resistantmice experienced a rise in regulatory B cells (𝑃 = 0.001) and, to a lower extent, in regulatory T cells (𝑃 = 0.02)
compared with C57BL/6 susceptible mice. As a consequence, MOG
35−55
-immunized C57BL/6 mice showed higher percentages of
CD4+ T cells producing both IFN-gamma (𝑃 = 0.02) and IL-17 (𝑃 = 0.009) and higher serum levels of IL-17 (𝑃 = 0.04) than
resistant mice. Conclusions. Expansion of regulatory B and T cells contributes to the induction of resistance to EAE by an MHC-
independent mechanism.
1. Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease
of the central nervous system (CNS). Numerous evidences
strongly suggest that it is an autoimmune disease in which
activated T cells enter the CNS and trigger an inflamma-
tory cascade resulting in demyelination and axonal loss.
Different genetic and environmental factors have shown to
play a role in MS susceptibility, being class II alleles of the
major histocompatibility complex (MHC), the more closely
associated genes [1], and infectious agents such as Epstein-
Barr virus, the environmental factors that have been more
clearly associated withMS susceptibility [2]. Conversely, high
serum levels of vitamin D have a protective role, delaying
the appearance of a second demyelinating event after a
clinically isolated syndrome [3]. It has been described that
this action can be mediated by upregulation of regulatory T
cells (Treg) [4] and B cells (Breg) [5]. It was also described
that MS patients suffer from a peripheral B cell tolerance
defect that may be attributable to impaired Treg function [6]
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and that proliferation of Breg induced by intestinal helminth
infections ameliorates MS course [7].
The role of regulatory cells in demyelinating dis-
eases has been also explored in experimental autoimmune
encephalomyelitis (EAE), a widely used animal model of MS
in which T cell mediates CNS demyelination [8]. EAE can be
induced in several species by immunizationwithmyelin anti-
gens or via adoptive transfer of myelin-reactive T cells [9, 10].
Adoptive transfer of Breg reduced significantly the severity
of EAE by inhibiting Th1 and Th17 inflammatory responses
[11]. Likewise, expansion of Treg diminished the infiltration
of inflammatory cells into the CNS and improved clinical
signs of EAE [12]. These data strongly suggest that deficits
in regulatory pathways may contribute to the induction of
autoimmune reactivity in EAE. These experimental models
may be useful tools to identify immunological mechanisms
mediating a protective role in demyelinating diseases.
Several strains of mice are resistant to develop EAE
as mice are asymptomatic following immunization with
myelin antigens [13]. It was argued that a poor recogni-
tion of encephalitogenic peptides by MHC molecules might
contribute to resistance to EAE. However, other immune
mechanismsmay also contribute to inducing resistance to the
disease. We explored them in two mouse strains, CD1 and
C57BL/6, that are, respectively, resistant and susceptible to
EAE induced by themyelin oligodendrocyte glycoprotein 35–
55 peptide (MOG
35−55
). Since CD1 is an outbred strain, these
mice do not share a unique MHC haplotype, which makes
this model useful to study MHC-independent mechanisms
that mediate resistance to this experimental model of MS.
We explored Breg and Treg in both strains and studied if
variations in regulatory cells associated with downregulation
of effector immune mechanisms.
2. Materials and Methods
2.1. Mice. Eight-to-ten-week-old female C57BL/6J mice,
which are susceptible to EAE induction byMOG
35−55
immu-
nization, were purchased from Harlan (Barcelona, Spain).
Age- and sex-matched CD1 mice that are resistant to EAE
induction were obtained from our own conventional barrier
protection breeding colony (Cajal Institute, CSIC, Madrid,
Spain). Mice were housed under standardized light- and
climate-controlled conditions and were fed with standard
chow and water ad libitum. Experiments were done in com-
pliance with the guidelines of animal care set by the European
Union (86/609/EEC), and all animal protocols were approved
by the Cajal Institute animal welfare committee (Protocol N
IORG0006540).
2.2. EAE Induction. For immunization C57BL/6 and CD1
mice were injected subcutaneously on day 0 with 200 𝜇L of
an emulsion containing 300 𝜇g of MOG
35−55
(CNB, CSIC,
Madrid, Spain) and 800 𝜇g of heat killed Mycobacterium
tuberculosisH37RA (Difco, BD Diagnostics, MD) emulsified
in incomplete Freund adjuvant oil (Sigma-Aldrich, St. Louis,
MO). In addition, the mice received 100 ng of Bordetella per-
tussis toxin (Sigma-Aldrich) intraperitoneally on days 0 and 2
after immunization (p.i.). Mice from both strains C57BL/6 or
CD1 were immunized in the same way using the 139–151 pep-
tide of proteolipid protein (PLP
139−151
) (Proteomics Section,
Universitat Pompeu Fabra, Barcelona, Spain) for comparison
with MOG
35−55
as C57BL/6 mice do not develop EAE fol-
lowing immunization with PLP peptide. Age-matched na¨ıve
C57BL/6 or CD1 mice were considered as control groups.
Mice were monitored daily, and clinical signs of EAE
were graded as follows: Grade 0, normal; Grade 1, flaccid tail;
Grade 2,mild hind-limbweakness; Grade 3, severe hind-limb
weakness; Grade 4, hind-limb paralysis; Grade 5, hind-limb
paralysis and partial fore-limb weakness.
2.3. Experimental Procedure. On the basis of previous reports
[14] we selected day 21 p.i. as the time point in which
experimental procedures were performed. Mice were anaes-
thetized by intraperitoneal administration of EuTalender
(Normonlab, Madrid, Spain). Blood samples were collected
by intracardiac puncture. Serum was obtained and frozen at
−80∘C until soluble cytokines and antibodies were assayed.
Spleens were removed and splenocyte suspensions were gen-
erated by grinding spleens through a wire mesh. Lymphocyte
subsets and intracellular cytokine production were tested in
freshly isolated splenocytes.
2.4. Splenocyte Proliferation Assay. The splenocytes were
seeded in 96-well plates at a cell density of 2 × 105 cells/well
in Iscove’s modified Dulbecco’s medium (IMDM; PAA Labo-
ratories GmbH, Pasching, Austria) supplemented with 10%
HyClone FetalClone I (Thermo Fisher Scientific, Waltham,
MA, USA), 50 𝜇mol/L of 2-mercaptoethanol (Sigma Chem-
ical), 2mmol/L of glutamine, 50 U/mL of penicillin, and
50mg/mL of streptomycin; the last three chemicals were
obtained from Gibco BRL (Paisley, UK). For splenocyte
activation, we used 5𝜇g/mLofMOG
35−55
, PLP
139−151
, or phy-
tohaemagglutinin (PHA; Sigma Chemical). Cells were incu-
bated in a humidified atmosphere at 5% CO
2
and 37∘C for 3
days, the last 18–20 h in the presence of 1 𝜇Ci/well of [3H]-
thymidine (PerkinElmer Inc., USA). The levels of incorpo-
rated radioactivity were determined using a beta-scintillation
counter (Wallac, Turku, Finland). The stimulation index (SI)
was expressed as the mean of the counts per minute (cpm) of
five replicates from eachmouse and culture condition divided
by themean cpmof the baseline control replicates.The results
are expressed as the mean value± standard error of the mean
(SEM) of the SI per group of mice.
2.5. Study of B and T Cell Subsets. We performed this study
in series of seven mice per condition. To study lymphocyte
subsets, cells were resuspended at 106/mL and incubated with
rat anti-mouse CD16/32 Fc receptor (FcR) (CD16/CD32) dur-
ing 10 minutes to avoid unspecific staining. Then, they were
incubated with the appropriate combinations of monoclonal
antibodies (BD Pharmingen, San Diego, CA) for 20 minutes
at 4∘C. Cells were washed with PBS and flow-cytometry
analysis was performed on FACScanto II (Becton Dickinson)
and analyzed using the DIVA software (Becton Dickinson).
As strategy for flow-cytometry analysis, an initial region
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was set around cells expressing intermediate to high CD45
with low-to-intermediate side scatter (P1) and then a second
region was set on the forward/side scatter dot plot to exclude
debris or apoptotic cells (P2). Only cells included in P1 and
P2 regions were accepted for analysis. We used the following
monoclonal antibodies: anti-CD4-FITC, anti-CD8a-PE, anti-
CD45-Cy5.5PerCP, anti-CD25-APC, anti-B220-FITC, anti-
CD1d-PE, and anti-CD5-APC, and isotype controls conju-
gated with FITC, PE, Cy5.5PerCP, and APC.
2.6. Analysis of Intracellular Cytokine Production. Spleno-
cytes were resuspended (106 cells/mL) in complete medium
[RPMI supplemented with 2mM glutamine, 2mg/mL gen-
tamycin (all fromGibco BRL (Paisley, UK)), and 10% fetal calf
serum (Biowhittaker technologies, MD, USA)] and the cells
were cultured for four hours with PMA (50 ng/mL; Sigma-
Aldrich, St. Louis, MO), ionomycin (500 ng/mL; Sigma-
Aldrich), and monensin (2𝜇M; eBioscience, San Diego, CA).
For IL-17A and IFN-gamma detection, FcR were blocked
with anti-CD16/CD32 antibody (BD Pharmingen) for 10
minutes at room temperature before cell surface staining.
Cells were stainedwith antibodies against surface antigens for
30min at 4∘C using predetermined optimal concentrations
of each antibody. Stained cells were fixed and permeabilized
using a Cytofix/Cytoperm kit (BD Pharmingen), according
to the manufacturer’s instructions, and stained with anti-IL-
17A-PE and anti-IFN-gamma-APC for 30min at 4∘C. After
washing cells, flow-cytometry analysis was performed on
FACScanto II (Becton Dickinson) and analyzed using the
DIVA software (Becton Dickinson).
2.7. Quantification of SerumCytokines. Serum cytokineswere
determined by a Milliplex map mouse cytokine panel (Mil-
lipore, Billerica, MA) following manufacturer instructions.
Data were analyzed in a TM100 cytometer (Labscan, Gliwice,
Poland).
2.8. Detection of Anti-MOG
35−55
Antibodies. Maxisorp
microtiter plates (Nunc, Roskilde, Denmark) were coated
overnight at 4∘C with 100 𝜇L/well of mouse MOG
35−55
peptides (CNB, CSIC) at a concentration of 10𝜇g/mL in
0.1M carbonate buffer, pH 9.7. Plates were washed with PBS
containing 0.02%Tween 20 and blockedwith 0.1M carbonate
buffer, pH 9.7, containing 5% BSA for 1 h at 37∘C.Then, plates
were incubated with triplicate serum samples diluted at 1/200
for 1 h at 37∘C and washed and incubated with biotinylated
anti-mouse IgM (Sigma-Aldrich) or anti-mouse IgG (Jackson
Immunoresearch, Suffolk, UK) for 1 h at 37∘C. After this, they
were washed and incubated with streptavidin-horseradish
peroxidase (Roche, Basel, Switzerland) for 30min at 37∘C.
After a final wash, the reaction products were visualized
usingOPD (Sigma-Aldrich) as a substrate and read at 492 nm
with a microplate reader (Thermo Fisher, Cambridge, UK).
2.9. Statistical Analysis. Results were analyzed with Prism
5.0 statistical package. We used Mann-Whitney 𝑈 test for
comparisons between groups. 𝑃 values lower than 0.05 were
considered significant.
Experiments were always performed in two independent
series ofmice using four animals per condition.We combined
them for the final statistical analysis. Results are always
expressed as mean ± SEM.
3. Results
We explored regulatory and effector immune mechanisms in
CD1 and C57BL/6 mice immunized with MOG
35−55
, using
as controls nonimmunized mice and mice immunized with
PLP
139−151
, a myelin peptide that is not capable of inducing
EAE in any of those mouse strains.
3.1. Splenocyte Proliferative Response. We tested the poly-
clonal and antigen-specific proliferative capacity of spleno-
cytes 21 days after the immunization. A diminished prolif-
eration showing a clear statistical trend (𝑃 = 0.056) was
detected in the resistant strain when a polyclonal stimulus
such as PHA was used (Figure 1). Moreover, upon antigen-
specific stimulation, the splenocytes from CD1 resistant
mice did not proliferate, while those of C57BL/6 susceptible
mice did (𝑃 = 0.016, Figure 1). Control study using
irrelevant PLP
139−151
peptide as stimulus did not render
proliferation in any of the strains. All these data indicate
that despite their heterogeneous MHC antigens, all CD1
resistant mice are unable to develop a T cell response against
the MOG
35−55
encephalitogenic peptide. We next aimed to
explore immunological mechanisms that contribute to this
phenomenon.
3.2. B Cell Subsets. We first examined B1 and B2 subsets
(Figures 2(a) and 2(b)). We did not found differences in
the percentages of T cell dependant B2 cells (B220+CD5−)
between resistant and susceptible mice (nonimmunized or
immunizedwithMOGor PLP peptides). Conversely, the per-
centage of innate B220+CD5+ B cells was downmodulated in
C57BL/6mice after EAE induction byMOG
35−55
(𝑃 = 0.005)
when compared with CD1 resistantmice immunized with the
same peptide. These differences were due to the regulatory
B220+CD5+CD1dhi B cell subset (Breg). When exploring
these B cells, we detected a decrease of Breg in C57BL/6 mice
suffering EAE (𝑃 = 0.02, Figures 2(c) and 2(d)). Conversely,
resistant CD1 strain upregulated this subpopulation after
immunization with MOG
35−55
(𝑃 = 0.03). These differences
between the two strains (𝑃 = 0.001) were only observed
upon MOG
35−55
immunization. By contrast, Breg remained
unchanged in either resistant or susceptible mice immunized
with the PLP
139−151
irrelevant peptide. This strongly suggests
that Breg are specifically triggered to prevent the autoimmune
process and have an important role in inducing resistance to
EAE.
3.3. Regulatory T Cells. Breg may contribute to the differ-
entiation of regulatory T cells (Treg) [15]. We also explored
this T cell subset (CD4+, CD25hi) in our series of mice
(Figure 3). Upon immunization with MOG
35−55
resistant
but not susceptible mice upregulated Treg (𝑃 = 0.028).
No differences were found in this T cell subset between
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Table 1: Titers of anti-MOG serum antibodies and T cell and B cell percentages in spleen of mice resistant (CD1) and susceptible (C57BL/6)
to MOG
35–55 induced EAE.
Nonimmunized MOG
35–55-immunized PLP139–151-immunized
C57BL/6 CD1 𝑃 C57BL/6 CD1 𝑃 C57BL/6 CD1 𝑃
MOG-IgG (OD492 nm) 0.24 ± 0.02 0.17 ± 0.07 0.59 0.12 ± 0.03 0.16 ± 0.03 0.34 0.27 ± 0.07 0.07 ± 0.03 0.11
MOG-IgM (OD492 nm) 0.15 ± 0.03 0.06 ± 0.04 0.10 0.12 ± 0.07 0.05 ± 0.02 0.62 0.04 ± 0.01 0.06 ± 0.03 0.47
% CD4+ T cells 17.8 ± 0.96 13.5 ± 1.63 0.11 17.04 ± 3.22 12.8 ± 3.12 0.48 19.8 ± 3.33 11.5 ± 1.79 0.11
% CD8+ T cells 27.4 ± 1.53 20.3 ± 2.78 0.11 28.0 ± 3.30 24.3 ± 1.69 0.34 21.5 ± 1.02 18.0 ± 3.34 0.34
We studied nonimmunized mice and mice immunized with MOG35–55 and PLP139–151. We used eight animals per condition. Values are expressed as mean ±
standard error. No differences were found in the levels of IgM or IgG anti-MOG35–55 antibodies expressed as optical density at 492 nm, in the percentages of
CD4+ and CD8+ T lymphocytes, and total B cells (B220+) between the different experimental groups.
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Figure 1: Proliferative capacity of splenocytes from C57BL/6 (susceptible strain) and CD1 (resistant strain) mice. We analyzed proliferative
capacity in series of seven mice per condition. Splenocytes from resistant and susceptible mice were stimulated with a polyclonal stimulus
(PHA), MOG
35−55
, or PLP
139−151
. Susceptible mice showed a higher proliferative capacity upon PHA stimulation and a statistically significant
augmented proliferation upon MOG stimulation. Conversely, splenocytes from both strains did not proliferate when the stimulus used was
139–151 PLP peptide.
resistant and susceptible strains when nonimmunized mice
ormice immunizedwith the PLP
139−151
peptide were studied.
These observations indicate that Treg may also play a role
in resistance to EAE shown by CD1 mice immunized with
MOG
35−55
.
3.4. Effector Responses. We did not find differences in the
levels of IgM or IgG anti-MOG
35−55
antibodies or in total
CD4+ and CD8+ T cell percentages between the resistant
and the susceptible mice (Table 1). To further discriminate
different T cell responses, we analyzed Th1 and Th17 sub-
sets. We explored the percentage of CD4+ T cells showing
intracellular production of IFN-gamma (Figure 4) and IL-
17 (Figure 5) upon stimulation with phorbol-12-myristate-13-
acetate (PMA) and ionomycin. Only susceptible mice that
developed EAE in response to MOG
35−55
showed significant
increases in the secretion of IFN-gamma (𝑃 = 0.02) and
IL-17 (𝑃 = 0.009) compared to resistant mice. By contrast,
resistant mice were unable to mount any of these responses
after the same immunization protocol. In addition, when
studying serum inflammatory cytokines, we detected a sig-
nificant increase of IL-17 in susceptible mice immunized with
MOG
35−55
(Figure 4(c)).This shows that downmodulation of
regulatory B andT cells is related to the induction ofTh1/Th17
responses in MOG-induced EAE.
4. Discussion
The understanding of the immune mechanisms involved
in resistance/susceptibility to EAE is important, as it may
contribute to identification of new therapeutic targets in
MS. The role of MHC by inducing defective or appropri-
ate presentation of the encephalitogenic peptide has been
previously demonstrated [16]. However, different evidences
suggest that induction of Breg may also contribute to the
resistance to EAE. They are necessary to induce Treg medi-
ated recovery from EAE [15]. Moreover, depletion of Breg
exacerbates EAE symptoms and increases encephalitogenic
T cell influx into the CNS [11]. In addition, induction
of Breg in MOG-immunized-C57BL/6 mice treated with
antibiotics ameliorates EAE course, and this effect can be
transferred to other C57BL/6 mice by passive transfer of
these B cells. Here, we aimed to explore if Breg may be a
MHC-independent mechanism for inducting resistance to
Journal of Immunology Research 5
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Figure 2: Effector and regulatory B cells in spleens of C57BL/6 and CD1 mice. We analyzed these cells in series of seven mice per condition.
(a) B2 cells (B220+CD5−) did not change significantly in mice immunized with MOG
35−55
(MOG) or PLP
139−151
(PLP) when compared
with nonimmunized (NI) ones. (b) B1 cell (B220+CD5+) percentage diminished in C57BL/6 mice that developed EAE upon immunization
with MOG
35−55
. (c) The B220+CD5+CD1dhi regulatory subset (Breg) increased in resistant CD1 mice immunized with MOG. Conversely, it
decreased in susceptible C57BL/6mice developing EAE after immunization with the same peptide. (d) Representative dot plots showing Breg
induced in CD1 (left side) and C57BL/6 (right side) mice upon immunization with MOG
35−55
peptide. Total B cells were gated by selecting
B-220 positive cells and then Breg were identified by CD5 and CD1dhi staining.
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Figure 3: Regulatory T cells in spleens of resistant and susceptible mice. We analyzed these cells in series of seven mice per condition.
(a) We studied nonimmunized mice (NI) and mice immunized with MOG
35−55
(MOG) and with PLP
139−151
(PLP). CD1 mice upregulated
CD4+CD25hi T cells when immunized with MOG or PLP autopeptides. Conversely, Treg percentages did not increase in C57BL/6 mice
immunized with MOG that developed EAE. (b) Representative dot plots showing regulatory T cells induced in CD1 (left side) and C57BL/6
(right side) mice upon immunization with MOG
35−55
peptide.
MOG-inducedEAE.We explored this inC57BL/6, a congenic
mouse strain susceptible to MOG
35−55
-induced EAE, and in
CD1 an outbred strain resistant toMOG
35−55
-induced EAE in
an MHC-independent manner. We immunized both strains
of mice with the encephalitogenic peptide and observed
that CD1 splenocytes were incapable of proliferating when
stimulated withMOG
35−55
.We next explored immunological
mechanism associated with this phenomenon and observed
that susceptible C57BL/6 mice developing the disease after
MOG
35−55
immunization downregulate Breg, while CD1
resistant mice show a significant increase of these cells upon
immunization with the same peptide. This strongly suggests
that Breg play a role in the induction of resistance to EAE in
CD1 mice.
Breg may regulate inflammatory responses by themselves
and by inducing Treg [15]. It was recently shown that Treg
are less suppressive in patients with MS [17]. In addition, an
increase of Treg may prevent the onset of EAE [18]. In the
present study we found that, in parallel with Breg findings,
resistant mice upregulated Treg. This seems to indicate that
Treg also have a role in resistance to MOG-induced EAE.
However, the immunization of C57BL/6 mice with the
PLP
139−151
peptide, which is incapable of inducing EAE in
this strain in an MHC-dependent manner [19], did not
induce significant changes in Breg or Treg subsets. We found
no significant changes in both Breg and Treg. This clearly
shows that whenMHCmolecules impede the correct peptide
presentation, regulatory responses are not triggered as it
happens in the outbred mice.
To further study differences between resistant and sus-
ceptible mice, we explored effector responses in the same
series of mice. It has been reported that antibodies may have
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Figure 4: Intracellular production of interferon-gamma (IFN-gamma) by spleen CD4+ T cells. We analyzed these cells in series of seven
mice per condition. (a) Splenocytes from C57BL/6 and CD1 mice were cultured in presence of phorbol-12-myristate-13-acetate (PMA) and
ionomycin during four hours, and the percentage of CD4+ T cells showing intracellular production of IFN-gamma was analyzed by flow
cytometry. We studied nonimmunized mice (NI) and mice immunized with MOG
35−55
(MOG) and with PLP
139−151
(PLP). C57BL/6 mice
that developed EAE after immunization with MOG
35−55
experienced a significant increase in the percentage of CD4+ T cells producing
IFN-gamma. (b) Representative dot plots of IFN-gamma intracellular staining on CD4+ T splenocytes from CD1 and C57BL/6 mice upon
immunization with MOG
35−55
.
beneficial or detrimental effects in demyelinating diseases
[20, 21]. In MOG-induced EAE model they are not related
to the initiation of the disease and it remains controversial
if they can influence disease severity [22, 23]. We tested
the presence of anti-MOG
35−55
IgM and IgG antibodies in
serum of resistant and susceptible mice. There were no sig-
nificant increases in anti-MOG
35−55
IgG or IgM responses in
MOG
35−55
-immunized mice of either susceptible or resistant
strains.This shows that IgMor IgGanti-MOG
35−55
antibodies
do not play a role in inducing susceptibility to MOG
35−55
-
induced EAE.
We next explored different spleen lymphocyte subsets.
Previous reports showed that CD4+ T cells are required
for the initial induction of progressive EAE and that the
disease is downregulated by CD8+ T cells [24]. Here, we
did not find differences in total CD4+ and CD8+ T cell
percentages between any of the groups of resistant and
susceptible mice. To further discriminate different T cell
responses, we analyzed effector Th1 and Th17 subsets. It has
been reported that IL-17 impairs the integrity of the blood
brain barrier in EAE [25] and that a rise of spleen Th17 cells
prolongs the disease [26]. Moreover, a decrease in IL-17 levels
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Figure 5: (a) Intracellular production of interleukin-17 (IL-17) by spleen CD4+ T cells. We analyzed these cells in series of seven mice per
condition. Splenocytes from C57BL/6 and CD1 mice were cultured in presence of phorbol-12-myristate-13-acetate (PMA) and ionomycin
during four hours and the percentage of CD4+ T cells showing intracellular production of IL-17 was analyzed by flow cytometry. We studied
nonimmunized mice (NI) and mice immunized with MOG
35−55
(MOG) and with PLP
139−151
(PLP). Only C57BL/6 mice that developed EAE
after immunization with MOG
35−55
displayed a significant increase in the percentage of CD4+ T cells producing IL-17. (b) Representative
dot plots of IL-17 intracellular production by CD4+ T cells from MOG
35−55
-immunized CD1 and C57BL/6 mice are shown. (c) Serum
concentrations of IL-17A in nonimmunized mice (NI) and mice immunized with MOG
35−55
(MOG).
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in supernatants of MOG
35−55
-activated splenocytes runs in
parallel with reduced demyelination and axonal damage in
mice with EAE [27]. We did not find significant differences
in the percentages of CD4+ cells secreting IFN-gamma or IL-
17 in nonimmunized mice. Conversely, we observed that sus-
ceptible mice that developed EAE in response to MOG
35−55
showed significant increases in the secretion of IFN-gamma
and IL-17. By contrast, resistant mice were unable to mount
any of these responses after the same immunization protocol.
In addition, serum levels of IL-17 were increased in suscepti-
ble mice immunized with MOG
35−55
. These data confirm the
importance of the induction ofTh1/Th17 responses in MOG-
induced EAE.
In conclusion, our data show that upregulation of B and,
to a lesser extent, of Treg, is closely associated with MHC-
independent resistance to MOG-induced EAE in CD1 mice
and with the abrogation of both Th1 and Th17 responses,
which have a critical role in the development of the disease.
These data help to ascertain the regulatory mechanisms than
can downmodulate inflammatory responses in demyelinating
diseases.
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